share_log

東陽光長江藥業:截至二零二四年一月三十一日止月份之股份發行人的證券變動月報表

HEC CJ PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024

香港交易所 ·  Feb 1 03:41
Summary by Moomoo AI
宜昌東陽光長江藥業股份有限公司(東陽光長江药业)於2024年1月31日向香港交易及結算所有限公司提交了最新的證券變動月報表。報告顯示,截至2024年1月底,公司的法定/註冊股本總額為879,967,700人民幣,其中H股股份數目維持在653,767,700股,每股面值1人民幣,無增減變動。內資股部分亦無變動,結存為226,200,000股。該報告亦確認,公司在報告期間內沒有股份期權、權證、可換股票據或其他相關股份變動。報告由聯席公司秘書彭琪雲於2024年2月1日呈交。
宜昌東陽光長江藥業股份有限公司(東陽光長江药业)於2024年1月31日向香港交易及結算所有限公司提交了最新的證券變動月報表。報告顯示,截至2024年1月底,公司的法定/註冊股本總額為879,967,700人民幣,其中H股股份數目維持在653,767,700股,每股面值1人民幣,無增減變動。內資股部分亦無變動,結存為226,200,000股。該報告亦確認,公司在報告期間內沒有股份期權、權證、可換股票據或其他相關股份變動。報告由聯席公司秘書彭琪雲於2024年2月1日呈交。
YICHANG EAST SUNSHINE CHANGJIANG PHARMACEUTICAL CO., LTD. (EAST SUNSHINE CHANGJIANG PHARMACEUTICALS) FILED ITS LATEST MONTHLY STATEMENT OF CHANGES IN SECURITIES WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON 31 JANUARY 2024. The report shows that as of the end of January 2024, the total authorized/registered share capital of the company was RMB879,967,700, of which the number of H shares remained at 653,767,700 shares with an face value of RMB 1 per share, without increase or decrease. The equity portion was unchanged, with 226,200,000 shares outstanding. The report also confirms that the Company had no change in stock options, warrants, convertible notes or other related shares during the reporting period. The report was presented by the Joint Secretary of the Joint Undertaking, Peng Chi-yun, on 1 February 2024.
YICHANG EAST SUNSHINE CHANGJIANG PHARMACEUTICAL CO., LTD. (EAST SUNSHINE CHANGJIANG PHARMACEUTICALS) FILED ITS LATEST MONTHLY STATEMENT OF CHANGES IN SECURITIES WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON 31 JANUARY 2024. The report shows that as of the end of January 2024, the total authorized/registered share capital of the company was RMB879,967,700, of which the number of H shares remained at 653,767,700 shares with an face value of RMB 1 per share, without increase or decrease. The equity portion was unchanged, with 226,200,000 shares outstanding. The report also confirms that the Company had no change in stock options, warrants, convertible notes or other related shares during the reporting period. The report was presented by the Joint Secretary of the Joint Undertaking, Peng Chi-yun, on 1 February 2024.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more